| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,968 | -15,984 |
| Stock-based compensation | 1,773 | 1,739 |
| Depreciation expense | 359 | 255 |
| Gain on sale of property and equipment | 8 | 8 |
| Prepaid expenses and other current assets | -1,484 | -1,169 |
| Operating lease right-of-use assets | -2,349 | -1,566 |
| Accounts payable | -619 | - |
| Accrued expenses and other current liabilities | -1,483 | - |
| Restructuring liability | -1,288 | - |
| Operating lease liabilities | -3,001 | - |
| Deferred revenue | -391 | - |
| Net cash used in operating activities | -22,793 | -15,432 |
| Purchases of property and equipment | 20 | 20 |
| Proceeds from the sale of property and equipment | 18 | 18 |
| Net cash (used in) provided by investing activities | -2 | -2 |
| Proceeds from sale of common stock, warrants and pre-funded warrants | 4,999 | 4,999 |
| Payment of deferred offering costs | 726 | 358 |
| Net cash provided by financing activities | 4,273 | 4,641 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -18,522 | -10,793 |
| Cash and cash equivalents at beginning of period | 42,570 | - |
| Cash and cash equivalents at end of period | 24,048 | - |
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)